Sana Biotechnology, Inc. Operating Lease, Right-of-Use Asset, Amortization Expense
Sana Biotechnology, Inc. (SANA) reported Operating Lease, Right-of-Use Asset, Amortization Expense of $2.96 million for the 6-month period ending 2026-06-30, per its 10-Q filed 2026-08-10.
Financial Statements › Cash Flow › Operating Activities
us-gaap:OperatingLeaseRightOfUseAssetAmortizationExpense · last filed 2026-08-10
- Sana Biotechnology, Inc. operating lease, right-of-use asset, amortization expense for the quarter ending 2026-06-30 was $490.00K, a 78.03% decline year-over-year.
- Sana Biotechnology, Inc. operating lease, right-of-use asset, amortization expense for the quarter ending 2026-03-31 was $2.47M, a 10.52% increase year-over-year.
- Sana Biotechnology, Inc. operating lease, right-of-use asset, amortization expense for the quarter ending 2025-12-31 was $2.39M, a 9.68% increase year-over-year.
- Sana Biotechnology, Inc. operating lease, right-of-use asset, amortization expense for the quarter ending 2025-09-30 was $2.32M, a 9.60% increase year-over-year.
- Sana Biotechnology, Inc. operating lease, right-of-use asset, amortization expense for fiscal 2025 was $9.17M, a 5.27% decline from fiscal 2024.
- Sana Biotechnology, Inc. operating lease, right-of-use asset, amortization expense for fiscal 2024 was $9.68M, a 27.02% decline from fiscal 2023.
- Sana Biotechnology, Inc. operating lease, right-of-use asset, amortization expense for fiscal 2023 was $13.27M, a 9.57% increase from fiscal 2022.
- Sana Biotechnology, Inc. operating lease, right-of-use asset, amortization expense for fiscal 2022 was $12.11M, a 76.88% increase from fiscal 2021.
| Period end | Operating Lease, Right-of-Use Asset, Amortization Expense 3 month | Operating Lease, Right-of-Use Asset, Amortization Expense 6 month | Operating Lease, Right-of-Use Asset, Amortization Expense 9 month | Operating Lease, Right-of-Use Asset, Amortization Expense 12 month |
|---|---|---|---|---|
| 2026-06-30 | $490.00K derived: 10-Q 6 month − 10-Q 3 month · filed 2026-08-10 | $2.96M 10-Q · filed 2026-08-10 | $5.35M derived: sum of 3 quarters · filed 2026-08-10 | $7.67M derived: sum of 4 quarters · filed 2026-08-10 |
| 2026-03-31 | $2.47M 10-Q · filed 2026-05-11 | $4.86M derived: sum of 2 quarters · filed 2026-05-11 | $7.18M derived: sum of 3 quarters · filed 2026-05-11 | $9.41M derived: sum of 4 quarters · filed 2026-08-10 |
| 2025-12-31 | $2.39M derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-03 | $4.71M derived: sum of 2 quarters · filed 2026-03-03 | $6.94M derived: sum of 3 quarters · filed 2026-08-10 | $9.17M 10-K · filed 2026-03-03 |
| 2025-09-30 | $2.32M derived: 10-Q 9 month − 10-Q 6 month · filed 2025-11-06 | $4.55M derived: sum of 2 quarters · filed 2026-08-10 | $6.78M 10-Q · filed 2025-11-06 | $8.96M derived: sum of 4 quarters · filed 2026-08-10 |
| 2025-06-30 | $2.23M derived: 10-Q 6 month − 10-Q 3 month · filed 2026-08-10 | $4.46M 10-Q · filed 2026-08-10 | $6.64M derived: sum of 3 quarters · filed 2026-08-10 | $8.76M derived: sum of 4 quarters · filed 2026-08-10 |
| 2025-03-31 | $2.23M 10-Q · filed 2026-05-11 | $4.41M derived: sum of 2 quarters · filed 2026-05-11 | $6.53M derived: sum of 3 quarters · filed 2026-05-11 | $8.58M derived: sum of 4 quarters · filed 2026-05-11 |
| 2024-12-31 | $2.18M derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-03 | $4.29M derived: sum of 2 quarters · filed 2026-03-03 | $6.34M derived: sum of 3 quarters · filed 2026-03-03 | $9.68M 10-K · filed 2026-03-03 |
| 2024-09-30 | $2.11M derived: 10-Q 9 month − 10-Q 6 month · filed 2025-11-06 | $4.16M derived: sum of 2 quarters · filed 2025-11-06 | $7.50M 10-Q · filed 2025-11-06 | $10.73M derived: sum of 4 quarters · filed 2026-03-03 |
| 2024-06-30 | $2.05M derived: 10-Q 6 month − 10-Q 3 month · filed 2025-08-11 | $5.39M 10-Q · filed 2025-08-11 | $8.62M derived: sum of 3 quarters · filed 2026-03-03 | $11.90M derived: sum of 4 quarters · filed 2026-03-03 |
| 2024-03-31 | $3.34M 10-Q · filed 2025-05-08 | $6.57M derived: sum of 2 quarters · filed 2026-03-03 | $9.85M derived: sum of 3 quarters · filed 2026-03-03 | $13.25M derived: sum of 4 quarters · filed 2026-03-03 |
| 2023-12-31 | $3.23M derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-03 | $6.51M derived: sum of 2 quarters · filed 2026-03-03 | $9.91M derived: sum of 3 quarters · filed 2026-03-03 | $13.27M 10-K · filed 2026-03-03 |
| 2023-09-30 | $3.28M derived: 10-Q 9 month − 10-Q 6 month · filed 2024-11-08 | $6.68M derived: sum of 2 quarters · filed 2024-11-08 | $10.03M 10-Q · filed 2024-11-08 | $13.28M derived: sum of 4 quarters · filed 2025-03-17 |
| 2023-06-30 | $3.40M derived: 10-Q 6 month − 10-Q 3 month · filed 2024-08-08 | $6.75M 10-Q · filed 2024-08-08 | $10.00M derived: sum of 3 quarters · filed 2025-03-17 | $13.18M derived: sum of 4 quarters · filed 2025-03-17 |
| 2023-03-31 | $3.35M 10-Q · filed 2024-05-08 | $6.60M derived: sum of 2 quarters · filed 2025-03-17 | $9.78M derived: sum of 3 quarters · filed 2025-03-17 | $12.85M derived: sum of 4 quarters · filed 2025-03-17 |
| 2022-12-31 | $3.25M derived: 10-K 12 month − 10-Q 9 month · filed 2025-03-17 | $6.42M derived: sum of 2 quarters · filed 2025-03-17 | $9.50M derived: sum of 3 quarters · filed 2025-03-17 | $12.11M 10-K · filed 2025-03-17 |
| 2022-09-30 | $3.18M derived: 10-Q 9 month − 10-Q 6 month · filed 2023-11-08 | $6.25M derived: sum of 2 quarters · filed 2023-11-08 | $8.86M 10-Q · filed 2023-11-08 | $11.11M derived: sum of 4 quarters · filed 2024-02-29 |
| 2022-06-30 | $3.08M derived: 10-Q 6 month − 10-Q 3 month · filed 2023-08-03 | $5.68M 10-Q · filed 2023-08-03 | $7.93M derived: sum of 3 quarters · filed 2024-02-29 | $9.69M derived: sum of 4 quarters · filed 2024-02-29 |
| 2022-03-31 | $2.61M 10-Q · filed 2023-05-08 | $4.85M derived: sum of 2 quarters · filed 2024-02-29 | $6.61M derived: sum of 3 quarters · filed 2024-02-29 | $8.05M derived: sum of 4 quarters · filed 2024-02-29 |
| 2021-12-31 | $2.25M derived: 10-K 12 month − 10-Q 9 month · filed 2024-02-29 | $4.01M derived: sum of 2 quarters · filed 2024-02-29 | $5.45M derived: sum of 3 quarters · filed 2024-02-29 | $6.84M 10-K · filed 2024-02-29 |
| 2021-09-30 | $1.76M derived: 10-Q 9 month − 10-Q 6 month · filed 2022-11-02 | $3.20M derived: sum of 2 quarters · filed 2022-11-02 | $4.60M 10-Q · filed 2022-11-02 | $5.96M derived: sum of 4 quarters · filed 2023-03-16 |
| 2021-06-30 | $1.44M derived: 10-Q 6 month − 10-Q 3 month · filed 2022-08-04 | $2.84M 10-Q · filed 2022-08-04 | $4.20M derived: sum of 3 quarters · filed 2023-03-16 | $5.30M derived: sum of 4 quarters · filed 2023-03-16 |
| 2021-03-31 | $1.40M 10-Q · filed 2022-05-10 | $2.76M derived: sum of 2 quarters · filed 2023-03-16 | $3.86M derived: sum of 3 quarters · filed 2023-03-16 | $4.86M derived: sum of 4 quarters · filed 2023-03-16 |
| 2020-12-31 | $1.36M derived: 10-K 12 month − 10-Q 9 month · filed 2023-03-16 | $2.46M derived: sum of 2 quarters · filed 2023-03-16 | $3.47M derived: sum of 3 quarters · filed 2023-03-16 | $4.25M 10-K · filed 2023-03-16 |
| 2020-09-30 | $1.10M derived: 10-Q 9 month − 10-Q 6 month · filed 2021-11-08 | $2.10M derived: sum of 2 quarters · filed 2021-11-08 | $2.89M 10-Q · filed 2021-11-08 | |
| 2020-06-30 | $1.01M derived: 10-Q 6 month − 10-Q 3 month · filed 2021-08-04 | $1.79M 10-Q · filed 2021-08-04 | ||
| 2020-03-31 | $784.00K 10-Q · filed 2021-05-05 | |||
| 2019-12-31 | $2.10M 10-K · filed 2022-03-16 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Candel Therapeutics, Inc. (CADL) | United States | $0.885B | -8.86 |
| Attovia Therapeutics, Inc. (ATTO) | United States | $0.828B | |
| Odyssey Therapeutics, Inc. (ODTX) | United States | $0.960B | |
| Solid Biosciences Inc. (SLDB) | United States | $0.802B | -5.07 |
| Cullinan Therapeutics, Inc. (CGEM) | United States | $0.993B | -5.72 |
| Monte Rosa Therapeutics, Inc. (GLUE) | United States | $1.002B | -12.81 |
| 4D Molecular Therapeutics, Inc. (FDMT) | United States | $0.733B | -4.10 |
| MeiraGTx Holdings plc (MGTX) | United States | $1.061B | 16.10 |
| Vor Biopharma Inc. (VOR) | United States | $1.091B | 1.60 |
| Aura Biosciences, Inc. (AURA) | United States | $0.639B | -5.61 |